ClinicalTrials.gg
CompletedNCT02688985Updated Jun 4, 2024Results posted

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

A Phase 3 interventional study of Ocrelizumab and Lumbar Puncture in Relapsing Multiple Sclerorsis and Multiple Sclerosis, Primary Progressive, sponsored by Genentech, Inc.. Completed at 17 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.

Enrollment
6th of 10
131 · median 184
Started
2016
the only one that year
Phase 3
7 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Genentech, Inc.

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 2nd registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, or all of them as a file.
02

Study summary

This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS. The study will be conducted in two cohorts i.e. RMS cohort (4 arm group) and PPMS cohort (one arm group). RMS cohort: Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions at Weeks 24 and 48. Participants will be randomized in 1:1:1 ratio to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52 following the first dose of ocrelizumab in three arm groups. A fourth RMS arm with delayed treatment start (Arm 4 [control group]) will not be a part of the randomization and will be recruited separately, wherein treatment with ocrelizumab will be delayed for 12 weeks from pre-treatment baseline. PPMS cohort: Ocrelizumab 600 mg will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks. Participants will receive a LP at the start of the study before dosing with ocrelizumab and second LP at Week 52 following the first dose of ocrelizumab. A long-term extension will be conducted for participants that complete the study and continue to receive ocrelizumab. Treatment with ocrelizumab in the entire study will continue for approximately 4.5 years after the first infusion.

03

Conditions studied

  • Relapsing Multiple Sclerorsis
  • Multiple Sclerosis, Primary Progressive
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

General Inclusion Criteria:

  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1 percent (%) per year during the treatment period and for at least 24 weeks after the last dose of study treatment or until their B-cells have repleted, whichever is longer

Inclusion Criteria Specific to RMS Participants:

  • Diagnosis of RMS in accordance with the 2010 revised McDonald criteria
  • Expanded Disability Status Scale (EDSS) score of 0 to 5.5 points, inclusive, at Screening
  • Disease duration from the onset of multiple sclerosis symptoms less than (\<) 15 years in participants with an EDSS score greater than (>) 5.0 at Screening
  • Either treatment-naive or receiving treatment with disease-modifying therapies, including prior use of interferon (IFN)-beta-1a (Avonex®, Rebif®), IFN-beta-1b (Betaseron®/Betaferon), or glatiramer acetate (Copaxone®).
  • At least one clinically documented relapse in the past year and/or at least one T1-weighted Gadolinium (Gd)-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment

Inclusion Criteria Specific to RMS Cohort Arm 4 Participants:

  • Must meet inclusion criteria for the RMS cohort
  • Separate signed Form for the RMS Delayed Time to Start Control Arm (Arm 4)
  • Must be willing to remain on the same dose and regimen of current standard of care, or no treatment if treatment-naïve, for 12 weeks after study enrollment The treating and/or study physician must agree that the participant is eligible to remain on the same dose and regimen of their current standard of care at Screening, or to receive no treatment if the participant is treatment-naïve, for 12 weeks after study enrollment

Inclusion Criteria Specific to PPMS Participants:

  • Diagnosis of PPMS in accordance with the 2010 revised McDonald criteria
  • EDSS score of 3.0 - 6.5 points, inclusive, at Screening
  • Disease duration from the onset of multiple sclerosis symptoms \<10 years in participants with an EDSS at Screening less than or equal to (\</=) 5.0
  • Documented history of either elevated immunoglobulin G (IgG) Index or one or more IgG oligoclonal bands (OCBs) detected by isoelectric focusing

Exclusion Criteria:

  • Diagnosis of secondary progressive multiple sclerosis without relapses for at least 1 year
  • History or known presence of recurrent or chronic infection (e.g., [HIV], syphilis, tuberculosis)
  • History of recurrent aspiration pneumonia requiring antibiotic therapy
  • History of cancer, including solid tumors and hematological (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology)
  • History of or currently active primary or secondary immunodeficiency
  • History of coagulation disorders
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • History of alcohol or other drug abuse within 24 weeks prior to enrollment
  • Known presence or history of other neurologic disorders Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including ), renal, hepatic, endocrine, gastrointestinal, or any other significant disease
  • Congestive heart failure (according to III or IV functional severity)
  • Known active bacterial, viral, fungal, mycobacterial infection, or any major episode of infection requiring hospitalization or treatment with IV antibiotics
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
  • or intolerance to oral or IV corticosteroids, including IV methylprednisolone, according to the country label
  • Contraindication for LP
  • Previous treatment with B cell-targeted therapies (such as rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
  • Previous treatment with natalizumab/Tysabri®, alemtuzumab, anti-CD4 agents, cladribine, teriflunomide, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
  • Treatment with fingolimod/Gilenya®, dimethyl fumarate/Tecfidera®, or similar treatment within 6 months prior to enrollment
  • Receipt of a within 6 weeks prior to enrollment
  • Systemic corticosteroid therapy within 4 weeks prior to Baseline
  • Previous or concurrent treatment with any agent or treatment with any experimental procedure for multiple sclerosis (such as treatment for chronic cerebrospinal venous insufficiency)
  • Certain laboratory abnormalities or findings at Screening
  • Inability to complete an MRI
  • Lack of peripheral venous access
  • Pregnant or lactating, or intending to become pregnant during the study

Exclusion Criteria Specific to RMS Participants:

  • Diagnosis of PPMS or secondary progressive multiple sclerosis without relapses
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    RMS Cohort Arm 1: Ocrelizumab + LP

    Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

    Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine

  • Experimental
    RMS Cohort Arm 2: Ocrelizumab + LP

    Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

    Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine

  • Experimental
    RMS Cohort Arm 3: Ocrelizumab + LP

    Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

    Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine

  • Experimental
    RMS Cohort Arm 4: Ocrelizumab + LP

    Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

    Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine

  • Experimental
    PPMS Cohort: Ocrelizumab + LP

    For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.

    Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine

Interventions

  • Ocrelizumab will be administered as IV infusion.

    Also known as: RO4964913

  • ProcedureLumbar Puncture

    Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

  • DrugMethyloprednisolone

    Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

  • Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

06

What researchers measure

Primary outcomes

  1. Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab

    Primary Analysis was based on following data-cut off: Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks

    Time frame: From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)

  2. Change in Number of CD19+ B Cells in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab

    Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks

    Time frame: From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)

  3. Change From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab

    Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks

    Time frame: From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)

07

Results

Posted Jun 4, 2024

Participant flow

131 patients enrolled at 17 study locations in the U.S., Canada, Germany, and Sweden

Participant flow — Overall Study
MilestoneRMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LP
Started2331281831
Completed00001
Not completed2331281830
Withdrew: Adverse event12200
Withdrew: Continued onto commercially available ocrelizumab1212141421
Withdrew: Death00001
Withdrew: Lack of efficacy00001
Withdrew: Lost to follow-up20111
Withdrew: Non-compliance with study drug13101
Withdrew: Other34100
Withdrew: Physician decision22001
Withdrew: Pregnancy00210
Withdrew: Study terminated by sponsor00010
Withdrew: Withdrawal by subject28714

Outcome measures

PrimaryChange in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab

Primary Analysis was based on following data-cut off: Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks

Time frame:
From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Reported as:
Mean · pg/mL
Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab
pg/mLRMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LP
Primary Analysis-1232.97 ± 2060.37-1169.13 ± 1739.49-1008.13 ± 1132.68-931.83 ± 2816.27261.85 ± 1175.72
LTE phase Week 144-2331.89 ± 3334.80-644.50 ± 1371.39-1287.58 ± 1822.72-2544.33 ± 3807.94-925.32 ± 2507.97
LTE phase Week 240-2499.98 ± 3606.71-791.51 ± 1150.89-1060.33 ± 1678.95-5488.70 ± 4350.46-1221.33 ± 2738.19
PrimaryChange in Number of CD19+ B Cells in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab

Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks

Time frame:
From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Reported as:
Mean · cells/μL
Change in Number of CD19+ B Cells in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab
cells/μLRMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LP
Primary Analysis-0.22 ± 0.26-0.15 ± 0.36-0.13 ± 0.32-0.18 ± 0.37-0.09 ± 0.11
LTE phase Week 144-0.11 ± 0.08-0.14 ± 0.20-0.06 ± 0.230.15 ± 0.10-0.01 ± 0.09
LTE phase Week 240-0.08 ± 0.09-0.20 ± 0.26-0.02 ± 0.01-0.04 ± 0.050.01 ± 0.03
PrimaryChange From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab

Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks

Time frame:
From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Reported as:
Mean · cells/μL
Change From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab
cells/μLRMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LP
Primary Analysis-6.61 ± 10.48-1.92 ± 3.15-1.46 ± 2.67-1.98 ± 5.10-3.25 ± 4.32
LTE phase Week 144-3.45 ± 2.331.78 ± 9.76-0.83 ± 4.642.25 ± 0.17-3.62 ± 5.56
LTE phase Week 240-3.00 ± 3.16-3.47 ± 2.31-1.41 ± 1.30-1.67 ± 2.42-1.37 ± 0.54

Adverse events

Collected over From baseline up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RMS Cohort Arm 1: Ocrelizumab + LP1/23 (4.3%)5/23 (21.7%)23/23 (100%)
RMS Cohort Arm 2: Ocrelizumab + LP0/31 (0%)5/31 (16.1%)28/31 (90.3%)
RMS Cohort Arm 3: Ocrelizumab + LP0/28 (0%)1/28 (3.6%)27/28 (96.4%)
RMS Cohort Arm 4: Ocrelizumab + LP0/18 (0%)5/18 (27.8%)17/18 (94.4%)
PPMS Cohort: Ocrelizumab + LP1/31 (3.2%)9/31 (29%)31/31 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventRMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LP
AppendicitisInfections and infestations2/230/310/281/181/31
COVID-19Infections and infestations0/231/310/281/181/31
Eye injuryInjury, poisoning and procedural complications0/230/310/281/180/31
InjuryInjury, poisoning and procedural complications0/230/310/281/180/31
Seronegative arthritisMusculoskeletal and connective tissue disorders0/230/310/281/180/31
Multiple sclerosis relapseNervous system disorders0/230/310/281/180/31
CellulitisInfections and infestations1/230/310/280/180/31
PneumoniaInfections and infestations1/230/310/280/181/31
Completed suicidePsychiatric disorders1/230/310/280/180/31
NeutropeniaBlood and lymphatic system disorders0/231/311/280/180/31
Most frequent other events
Showing 10 of 154
Most frequent other events
EventRMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LP
Upper respiratory tract infectionInfections and infestations7/236/3110/2812/1813/31
Infusion related reactionInjury, poisoning and procedural complications15/239/3116/2811/1812/31
Urinary tract infectionInfections and infestations4/235/315/287/1811/31
ArthralgiaMusculoskeletal and connective tissue disorders2/233/314/282/1811/31
SinusitisInfections and infestations4/2310/314/281/182/31
Back painMusculoskeletal and connective tissue disorders1/230/312/284/189/31
CoughRespiratory, thoracic and mediastinal disorders2/231/313/282/188/31
FatigueGeneral disorders1/232/313/284/185/31
COVID-19Infections and infestations4/232/311/284/185/31
Post lumbar puncture syndromeInjury, poisoning and procedural complications2/234/314/284/186/31

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LPTotal
<=18 years000000
Between 18 and 65 years2331281831131
>=65 years000000
Age, Continuous
Age, Continuous(Years)RMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LPTotal
Mean36.0 ± 10.438.7 ± 10.434.6 ± 10.836.4 ± 9.844.9 ± 7.438.5 ± 10.4
Sex/Gender, Customized
Sex/Gender, Customized(Participants)RMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LPTotal
Male89871648
Female152220111583
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LPTotal
Hispanic or Latino121026
Not Hispanic or Latino2228271728122
Unknown or Not Reported010113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RMS Cohort Arm 1: Ocrelizumab + LPRMS Cohort Arm 2: Ocrelizumab + LPRMS Cohort Arm 3: Ocrelizumab + LPRMS Cohort Arm 4: Ocrelizumab + LPPPMS Cohort: Ocrelizumab + LPTotal
American Indian or Alaska Native000000
Asian001113
Native Hawaiian or Other Pacific Islander000000
Black or African American231309
White2128251329116
More than one race000101
Unknown or Not Reported001012
08

Study locations

17 sites
  • Stanford University
    Palo Alto, California 94303, United States
  • University of California at San Francisco
    San Francisco, California 94115, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine ; Pulmonary & Critical Care
    New Haven, Connecticut 06510, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Washington University; Wash Uni. Sch. Of Med
    Saint Louis, Missouri 63110, United States
  • Empire Neurology, PC
    Latham, New York 12210, United States
  • Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr
    New York, New York 63110, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oklahoma Medical Research Foundation; MS Center of Excellence
    Oklahoma City, Oklahoma 73104, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-0001, United States
  • University of British Columbia Hospital Site; Djavad Mowafaghian Centre for Brain Health
    Vancouver, British Columbia V6T 1Z3, Canada
  • McGill University; Montreal Neurological Institute; Neurological and Psychiatric
    Montreal, Quebec H3A 2B4, Canada
  • Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
    Dresden, 01307, Germany
  • Universitätsmedizin Göttingen Georg-August-Universität
    Göttingen, 37075, Germany
  • Karolinska Universitetssjukhuset, Solna
    Stockholm, 113 41, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Apr 2023, 83 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Feb 23, 2016
StartActual
Apr 29, 2016
Primary completionActual
Apr 11, 2023
CompletionActual
Apr 11, 2023
Results first posted
Jun 4, 2024
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02688985
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
Apr 29, 2016
Primary completion
Apr 11, 2023
Completion
Apr 11, 2023
Results posted
Jun 4, 2024
Last update
Jun 4, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion